Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome

NCT00586183 | Completed

• 1 other identifier: 06-002093
• Study Type: interventional
• Target: 1
• Locations: 1 country
• Sites: 1

Brief Summary

Our hypothesis is that altered cardiac sympathetic activity is present and may contribute to the myocardial stunning observed in the apical ballooning syndrome. Aim: Assess the extent and reversibility of cardiac adrenergic neuronal dysfunction using carbon-11 hydroxyephedrine (C-11 HED), a positron emission tomography (PET) tracer, in patients with the apical ballooning syndrome.

Conditions

Apical Ballooning Syndrome

Keywords

Ventricular Remodeling

Outcome Measures

Primary Outcomes (1)

• Assess the extent and reversibility of cardiac adrenergic neuronal dysfunction

  During PET scan

Study Arms (1)

1

EXPERIMENTAL

The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.

Procedure: PET scan

Interventions

PET scan PROCEDURE

The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.

Also known as: Positron emission scan

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Transient akinesis or dyskinesis of the left ventricular apical and mid-ventricular segments with regional wall-motion abnormalities extending beyond a single epicardial vascular distribution.
• Absence of obstructive coronary disease or angiographic evidence of acute plaque rupture.
• New electrocardiographic abnormalities (either ST-segment elevation or T-wave inversion.
• Absence of recent significant head trauma, intracranial bleeding, pheochromocytoma, myocarditis, hypertrophic cardiomyopathy.

You may not qualify if:

• Hemodynamically unstable patients (requiring pressor support) will be excluded.
• Breastfeeding women.
• Pregnant women (urine pregnancy test required within 48 hours prior to each set of PET scans.

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Conditions

Takotsubo Cardiomyopathy; Ventricular Remodeling

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Cardiomyopathies; Heart Diseases; Cardiovascular Diseases; Ventricular Dysfunction, Left; Ventricular Dysfunction; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Spectrum Analysis; Chemistry Techniques, Analytical; Investigative Techniques

Study Officials

• Abhiram Prasad, MD

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: December 21, 2007
• First Posted: January 4, 2008
• Study Start: March 1, 2006
• Primary Completion: December 1, 2006
• Study Completion: December 1, 2006
• Last Updated: January 4, 2008

Record last verified: 2006-03

Locations

US (1)